GLP-2/Tirz vs PT-141 (Bremelanotide)
GLP-2/Tirz and PT-141 (Bremelanotide) are studied in overlapping research areas, which is why they are frequently compared. This is a neutral side-by-side reference drawn from published preclinical literature and laboratory handling data.
How they actually differ
Comparing the two: GLP-2/Tirz is lipidated dual receptor agonist (gip / glp-1), 39-residue chain, while PT-141 (Bremelanotide) is cyclic heptapeptide, melanocortin receptor agonist — different molecular classes with different handling consequences; their leading degradation routes differ (interfacial aggregation from agitation or freezing for GLP-2/Tirz, tryptophan photo-oxidation for PT-141 (Bremelanotide)), so the storage precautions that matter are not the same; their practical working windows differ once reconstituted. The sections below set out each in full.
GLP-2/Tirz — origin
GLP-2/Tirz is built on a GIP-based backbone rather than a GLP-1 one — an important and often-missed design detail. It was engineered from the GIP sequence and modified to acquire GLP-1 receptor activity, with a C20 fatty diacid attached via a linker for albumin binding. The term "twincretin" describes the dual incretin activity.
PT-141 (Bremelanotide) — origin
PT-141 is a metabolite of Melanotan II, and its history is an unusually direct case of a side effect becoming the research programme. Melanotan II was developed as a synthetic α-MSH analogue for pigmentation research; an unanticipated effect observed during that work redirected attention to the metabolite, which was then developed separately as bremelanotide.
GLP-2/Tirz research themes
Simultaneous GIP and GLP-1 receptor activity from a GIP-derived backbone.
Core metabolic research endpoints for the incretin class.
A well-characterised GLP-1 pathway effect studied in metabolic models.
Whether GIP agonism or antagonism is the productive direction remains an active research debate.
PT-141 (Bremelanotide) research themes
Acts at melanocortin receptors, with MC3R and MC4R the subtypes of research interest.
Distinguished in the literature by acting centrally, unlike vascular-mechanism compounds in adjacent research areas.
Its origin as a metabolite of a pigmentation-research compound is central to understanding its development history.
The lactam bridge restricts conformational freedom, a common strategy for improving receptor selectivity.
GLP-2/Tirz handling
- Swirl, never shake or vortex.
- Add diluent down the vial wall and give the cake time — several minutes of slow dissolution is normal, not a defect.
- Store upright and refrigerated; do not freeze once reconstituted.
PT-141 (Bremelanotide) handling
- Protect from light at all stages.
- Standard gentle reconstitution; the constrained ring is not agitation-sensitive in the way flexible long chains are.
- Store refrigerated and aliquot rather than repeatedly sampling one vial.
Both third-party tested
Every Popular Peptides batch of GLP-2/Tirz and PT-141 (Bremelanotide) is independently tested by HPLC and LC-MS with a published Certificate of Analysis. Enter a lot number to pull the COA for a specific vial.
GLP-2/Tirz reference
Related comparisons
GLP-2/Tirz and PT-141 (Bremelanotide) are supplied strictly as research chemicals for in-vitro laboratory and research use only. They are not intended for human or animal consumption, diagnostic, or therapeutic use. This comparison summarizes published preclinical literature and laboratory handling data; it is not medical advice, not a claim of efficacy, and not usage guidance.